Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epoetin alfa dosing schedules in cancer anemia
NCT01394991Phase 4Completed
- Sponsor
- Johnson & Johnson
- Start
- Jan 2006
- Primary completion
- Sep 2009
- Modality
- Biologic, rProtein (Recombinant Protein)
01
Overview
Phase 4, randomised, open-label trial of epoetin alfa (2 arms), sponsored by Johnson & Johnson. Primary endpoint: Number of Participants With at Least 1 Clinically Relevant and Objectively Confirmed Thrombovascular Event From Randomization Through Week 16. Started Jan 2006; status: completed.
02
Drugs
epoetin alfa
Beyond the preview
Go deeper on NCT01394991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01394991.